http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1315611-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C275-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-04 |
| filingDate | 1971-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1973-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1315611-A |
| titleOfInvention | Phenylalanine derivatives and a process for the manufacture thereof |
| abstract | 1315611 Pharmaceutical compositions containing dopa derivatives F HOFFMANN-LA ROCHE & CO AG 29 Oct 1971 [30 Oct 1970] 50330/71 Heading A5B [Also in Division C2] Pharmaceutical compositions having hypotensive, antipyretic or anti-Parkinson properties comprise a compound of formula: wherein R represents a hydrogen atom or an alkyl group, R 1 represents a hydrogen or halogen atom or an alkyl, alkoxy, nitro or dialkylamino group, R 2 represents (a) a phenylthio, alkylsulphonyl or phenylsulphonyl group, which groups may be substituted by hydroxy, alkoxy, alkylsulphonyl, halogen, nitro, cyano, alkyl-substituted aminocarbonyl, alkanoyloxy or alkyl, or (b) an alkanoyl group which is substituted by hydroxy, alkoxy, alkylthio, phenylthio (which may be alkyl-substituted), halogen, cyano, carboxy, alkoxycarbonyl, alkyl-substituted aminocarbonyl or alkanoyloxy, or (c) an alkoxycarbonyl or alkyl-substituted aminocarbonyl group, and R 3 represents a hydroxy group, an alkoxy group which may be phenyl substituted or an amino group which may be alkyl substituted, or a salt thereof and a carrier or diluent and optionally a peripheral decarboxylase inhibitor such as benzylidenacetophenone, L-3-(3, 4 dihydroxyphenyl)-2-methylalanine, a compound of formula: wherein P is H or an amino-C 2-7 alkanoyl group which may be hydroxy substiuted and n is 2 or 3, or a compound of formula: wherein Q is H or C 1-7 alkyl. The preparation may be in standard forms for enteral or parenteral administration. However when they contain a carboxylase inhibitor the above compound of formula I is preferably in a core which is coated with a substance resistant to gastric juice and then coated with a layer containing the carboxylase inhibitor. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8704154-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5075108-A |
| priorityDate | 1970-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.